Drug class
Selective P2X3 receptor antagonist; non-opioid antitussive
Mechanism of action
Selectively antagonises ATP-gated P2X3 receptors, with some activity at P2X2/3 receptors, on airway vagal sensory C-fibres. This reduces ATP-mediated sensory-nerve activation and the urge-to-cough signalling pathway.
General use cases
- Treatment of refractory or unexplained chronic cough in adults under the EU-authorised indication; local availability and authorisation vary by jurisdiction
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
